"MIATA"-minimal information about T cell assays.


Autoria(s): Janetzki, S.; Britten, C.M.; Kalos, M.; Levitsky, H.I.; Maecker, H.T.; Melief, C.J.; Old, L.J.; Romero, P.; Hoos, A.; Davis, M.M.
Data(s)

2009

Resumo

Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.

Identificador

https://serval.unil.ch/notice/serval:BIB_07A00768009A

info:pmid:19833080

https://serval.unil.ch/resource/serval:BIB_07A00768009A.P001/REF

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_07A00768009A7

urn:nbn:ch:serval-BIB_07A00768009A7

Idioma(s)

eng

Fonte

Immunity314527-528

Palavras-Chave #Cancer Vaccines/immunology; Cancer Vaccines/therapeutic use; Humans; Immunoassay/standards; Immunotherapy; Monitoring, Immunologic/standards; Neoplasms/therapy; Practice Guidelines as Topic/standards; T-Lymphocytes/immunology; Viral Vaccines/immunology; Viral Vaccines/therapeutic use; Virus Diseases/therapy
Tipo

info:eu-repo/semantics/article

article

Formato

application/pdf

Direitos

info:eu-repo/semantics/openAccess

Copying allowed only for non-profit organizations

https://serval.unil.ch/disclaimer